1-6 of 6
S. Suciu
Close
Sort by
Journal Articles

Incidence and Clinical Impact of TET2 Mutations in Acute Myeloid Leukemia Patients Treated within the EORTC/GIMEMA AML-12/06991 AML Trial.

M. G Aslanyan, S. M.C. Langemeijer, D. Cilloni, G. Saglio, JP Marie, R. Tang, B. Labar, R. Zadro, D. Batinic, S. Amadori, F. Lo Coco, T. Scheele, L. Kroeze, M. Massop, P. van Hoogen, E. Stevens, P. Muus, S. Suciu, L. Baila, E. W.A. Marijt, R. Willemze, T. de Witte, B. van der Reijden, J. H. Jansen
Journal: Blood
Blood (2009) 114 (22): 2609.
https://doi.org/10.1182/blood.V114.22.2609.2609
Published: 2009
Journal Articles

Allogeneic (Allo-) or Autologous (Auto-) Peripheral Blood Stem Cell Transplantation (SCT) Randomized Versus a Second Intensive Consolidation after a Common Induction and Consolidation Course in Patients with Bad Prognosis Myelodysplastic Syndromes and Acute Myelogenous Leukemia Following MDS of More Than 6 Months Duration: The Final Analysis of a Joint Study (CRIANT) of the EORTC, EBMT, SAKK, HOVON and GIMEMA Leukemia Groups.

T.M. De Witte, MD, A. Hagemeijer, MD, S. Suciu, PhD, A. Belhabri, MD, M. Delforge, MD, C. Aul, MD, M. Aivado, MD, D. Selleslag, MD, H. Schouten, MD, A. Ferrant, MD, H. Biersack, MD, S. Amadori, MD, P. Muus, MD, U. Jehn, MD, F. Beeldens, J. Jansen, PhD, E. Hellstrom-Lindberg, MD, T. Kovacsovics, MD, U. Hess, MD, P. Wijermans, MD, G. Ossenkoppele, MD, A. Gratwohl, MD, J.-P. Marie, MD, R. Willemze, MD
Journal: Blood
Blood (2005) 106 (11): 794.
https://doi.org/10.1182/blood.V106.11.794.794
Published: 2005
Journal Articles

A New Prognostic Disease Specific Model To Predict Survival after Intensive Antileukemic Treatment for Young Patients with Poor-Risk MDS and AML: Results of the CRIANT and AML-10 Studies Conducted by the EORTC/GIMEMA/SAKK/HOVON/EBMT Groups.

M. Oosterveld, MD, S. Suciu, M.Sc, P. Muus, MD, M. Delforge, MD, A. Belhabri, MD, C. Aul, MD, D. Selleslag, MD, A. Ferrant, MD, J.-P. Marie, MD, S. Amadori, MD, U. Jehn, MD, U. Hess, MD, R. Willemze, MD, E. Hellstrom-Lindberg, MD, M. Vignetti, MD, B. Labar, MD, F. Mandelli, MD, T. De Witte, MD
Journal: Blood
Blood (2004) 104 (11): 2020.
https://doi.org/10.1182/blood.V104.11.2020.2020
Published: 2004
Journal Articles

Up-Front Window Trial of Gemtuzumab Ozogamicin (GO) in Previously Untreated Elderly Patients with AML: An EORTC Leukemia Group Study.

Sergio Amadori, S. Suciu, R. Willemze, F. Mandelli, D. Selleslag, R. Stauder, A. Ho, C. Denzlinger, G. Leone, G. Fillet, P. Muus, F. Beeldens, O. Anak, T. De Witte
Journal: Blood
Blood (2004) 104 (11): 877.
https://doi.org/10.1182/blood.V104.11.877.877
Published: 2004
Journal Articles

Use of Recombinant Granulocyte-Macrophage Colony-Stimulating Factor During and After Remission Induction Chemotherapy in Patients Aged 61 Years and Older With Acute Myeloid Leukemia (AML): Final Report of AML-11, a Phase III Randomized Study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer (EORTC-LCG) and the Dutch Belgian Hemato-Oncology Cooperative Group (HOVON)

B. Löwenberg, S. Suciu, E. Archimbaud, G. Ossenkoppele, G.E.G. Verhoef, E. Vellenga, P. Wijermans, Z. Berneman, A.W. Dekker, P. Stryckmans, H. Schouten, U. Jehn, P. Muus, P. Sonneveld, M. Dardenne, R. Zittoun
Journal: Blood
Blood (1997) 90 (8): 2952–2961.
https://doi.org/10.1182/blood.V90.8.2952
Published: 1997
Journal Articles

Comparison of chemotherapy with immunotherapy for maintenance of acute lymphoblastic leukemia in children and adults

PA Stryckmans, J Otten, MJ Delbeke, S Suciu, D Fiere, J Bury, G Solbu, Y Benoit
Journal: Blood
Blood (1983) 62 (3): 606–615.
https://doi.org/10.1182/blood.V62.3.606.606
Published: 1983